Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	cytidine deaminase activity	APOBEC3H APOBEC3G APOBEC3A	4.96e-06	13	53	3	GO:0004126
GeneOntologyMolecularFunction	modification-dependent protein binding	ING1 WDR81 PEX1 ASCC2 MLLT1 PML	1.72e-05	206	53	6	GO:0140030
GeneOntologyMolecularFunction	deaminase activity	APOBEC3H APOBEC3G APOBEC3A	9.97e-05	34	53	3	GO:0019239
GeneOntologyMolecularFunction	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines	APOBEC3H APOBEC3G APOBEC3A	1.18e-04	36	53	3	GO:0016814
GeneOntologyMolecularFunction	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	APOBEC3H APOBEC3G ACY1 APOBEC3A	6.08e-04	146	53	4	GO:0016810
GeneOntologyMolecularFunction	transition metal ion binding	RAG1 KDM3A PARP1 TLL2 APOBEC3H APOBEC3G ALOXE3 PRDM2 APOBEC3A PML	1.01e-03	1189	53	10	GO:0046914
GeneOntologyMolecularFunction	ubiquitin-like protein reader activity	PEX1 PML	1.99e-03	25	53	2	GO:0140035
GeneOntologyMolecularFunction	K63-linked polyubiquitin modification-dependent protein binding	WDR81 ASCC2	2.16e-03	26	53	2	GO:0070530
GeneOntologyMolecularFunction	zinc ion binding	RAG1 PARP1 TLL2 APOBEC3H APOBEC3G PRDM2 APOBEC3A PML	2.27e-03	891	53	8	GO:0008270
GeneOntologyBiologicalProcess	DNA modification	PARP1 APOBEC3H APOBEC3G APOBEC3A	1.07e-06	31	52	4	GO:0006304
GeneOntologyBiologicalProcess	DNA cytosine deamination	APOBEC3H APOBEC3G APOBEC3A	1.79e-06	10	52	3	GO:0070383
GeneOntologyBiologicalProcess	cytidine to uridine editing	APOBEC3H APOBEC3G APOBEC3A	3.27e-06	12	52	3	GO:0016554
GeneOntologyBiologicalProcess	glycosyl compound metabolic process	APOBEC3H APOBEC3G LCMT2 APOBEC3A AKR7A2	4.30e-06	96	52	5	GO:1901657
GeneOntologyBiologicalProcess	cytidine catabolic process	APOBEC3H APOBEC3G APOBEC3A	5.39e-06	14	52	3	GO:0006216
GeneOntologyBiologicalProcess	DNA deamination	APOBEC3H APOBEC3G APOBEC3A	5.39e-06	14	52	3	GO:0045006
GeneOntologyBiologicalProcess	cytidine metabolic process	APOBEC3H APOBEC3G APOBEC3A	5.39e-06	14	52	3	GO:0046087
GeneOntologyBiologicalProcess	cytidine deamination	APOBEC3H APOBEC3G APOBEC3A	5.39e-06	14	52	3	GO:0009972
GeneOntologyBiologicalProcess	negative regulation of single stranded viral RNA replication via double stranded DNA intermediate	APOBEC3H APOBEC3G APOBEC3A	8.27e-06	16	52	3	GO:0045869
GeneOntologyBiologicalProcess	pyrimidine ribonucleoside metabolic process	APOBEC3H APOBEC3G APOBEC3A	8.27e-06	16	52	3	GO:0046131
GeneOntologyBiologicalProcess	pyrimidine ribonucleoside catabolic process	APOBEC3H APOBEC3G APOBEC3A	8.27e-06	16	52	3	GO:0046133
GeneOntologyBiologicalProcess	pyrimidine nucleoside catabolic process	APOBEC3H APOBEC3G APOBEC3A	1.20e-05	18	52	3	GO:0046135
GeneOntologyBiologicalProcess	regulation of single stranded viral RNA replication via double stranded DNA intermediate	APOBEC3H APOBEC3G APOBEC3A	1.42e-05	19	52	3	GO:0045091
GeneOntologyBiologicalProcess	base conversion or substitution editing	APOBEC3H APOBEC3G APOBEC3A	1.42e-05	19	52	3	GO:0016553
GeneOntologyBiologicalProcess	single stranded viral RNA replication via double stranded DNA intermediate	APOBEC3H APOBEC3G APOBEC3A	1.67e-05	20	52	3	GO:0039692
GeneOntologyBiologicalProcess	ribonucleoside catabolic process	APOBEC3H APOBEC3G APOBEC3A	3.77e-05	26	52	3	GO:0042454
GeneOntologyBiologicalProcess	pyrimidine nucleoside metabolic process	APOBEC3H APOBEC3G APOBEC3A	4.24e-05	27	52	3	GO:0006213
GeneOntologyBiologicalProcess	viral RNA genome replication	APOBEC3H APOBEC3G APOBEC3A	7.12e-05	32	52	3	GO:0039694
GeneOntologyBiologicalProcess	nucleoside catabolic process	APOBEC3H APOBEC3G APOBEC3A	7.12e-05	32	52	3	GO:0009164
GeneOntologyBiologicalProcess	clearance of foreign intracellular DNA	APOBEC3H APOBEC3A	9.29e-05	6	52	2	GO:0044355
GeneOntologyBiologicalProcess	clearance of foreign intracellular nucleic acids	APOBEC3H APOBEC3A	9.29e-05	6	52	2	GO:0099046
GeneOntologyBiologicalProcess	nucleobase-containing small molecule catabolic process	APOBEC3H APOBEC3G APOBEC3A	1.11e-04	37	52	3	GO:0034656
GeneOntologyBiologicalProcess	glycosyl compound catabolic process	APOBEC3H APOBEC3G APOBEC3A	1.51e-04	41	52	3	GO:1901658
GeneOntologyBiologicalProcess	nuclear receptor-mediated signaling pathway	KDM3A PARP1 ALOXE3 CNOT1 PML	1.53e-04	202	52	5	GO:0141193
GeneOntologyBiologicalProcess	positive regulation of double-strand break repair via homologous recombination	PARP1 WAS RNF126	1.86e-04	44	52	3	GO:1905168
GeneOntologyBiologicalProcess	pyrimidine-containing compound catabolic process	APOBEC3H APOBEC3G APOBEC3A	2.13e-04	46	52	3	GO:0072529
GeneOntologyBiologicalProcess	transposable element silencing	APOBEC3H APOBEC3G APOBEC3A	2.13e-04	46	52	3	GO:0010526
GeneOntologyBiologicalProcess	retrotransposition	APOBEC3H APOBEC3G APOBEC3A	2.41e-04	48	52	3	GO:0032197
GeneOntologyBiologicalProcess	ribonucleoside metabolic process	APOBEC3H APOBEC3G APOBEC3A	2.41e-04	48	52	3	GO:0009119
GeneOntologyBiologicalProcess	transposition	APOBEC3H APOBEC3G APOBEC3A	2.72e-04	50	52	3	GO:0032196
GeneOntologyBiologicalProcess	DNA metabolic process	RAG1 PARP1 WAS APOBEC3H ASCC2 APOBEC3G RNF126 GEN1 APOBEC3A PML	3.17e-04	1081	52	10	GO:0006259
GeneOntologyBiologicalProcess	negative regulation of viral genome replication	APOBEC3H APOBEC3G APOBEC3A	3.81e-04	56	52	3	GO:0045071
GeneOntologyBiologicalProcess	regulation of double-strand break repair	PARP1 WAS RNF126 PML	5.01e-04	146	52	4	GO:2000779
GeneOntologyBiologicalProcess	intracellular receptor signaling pathway	KDM3A PARP1 ALOXE3 ZDHHC3 CNOT1 PML	6.03e-04	416	52	6	GO:0030522
GeneOntologyBiologicalProcess	transforming growth factor beta receptor signaling pathway	PARP1 ING1 LPXN PXN PML	6.43e-04	276	52	5	GO:0007179
GeneOntologyBiologicalProcess	nucleoside metabolic process	APOBEC3H APOBEC3G APOBEC3A	6.75e-04	68	52	3	GO:0009116
GeneOntologyBiologicalProcess	transforming growth factor beta receptor superfamily signaling pathway	PARP1 ING1 PCSK6 LPXN PXN PML	8.57e-04	445	52	6	GO:0141091
GeneOntologyBiologicalProcess	regulation of stem cell population maintenance	KDM3A ING1 CNOT1	1.01e-03	78	52	3	GO:2000036
GeneOntologyBiologicalProcess	RNA modification	APOBEC3H APOBEC3G LCMT2 APOBEC3A	1.01e-03	176	52	4	GO:0009451
GeneOntologyBiologicalProcess	positive regulation of DNA recombination	PARP1 WAS RNF126	1.08e-03	80	52	3	GO:0045911
GeneOntologyCellularComponent	P-body	APOBEC3H APOBEC3G CNOT1 APOBEC3A	1.30e-04	102	53	4	GO:0000932
Domain	APOBEC_N	APOBEC3H APOBEC3G APOBEC3A	4.66e-06	12	53	3	PF08210
Domain	APOBEC_N	APOBEC3H APOBEC3G APOBEC3A	4.66e-06	12	53	3	IPR013158
Domain	APOBEC/CMP_deaminase_Zn-bd	APOBEC3H APOBEC3G APOBEC3A	7.68e-06	14	53	3	IPR016192
Domain	Cytidine_deaminase-like	APOBEC3H APOBEC3G APOBEC3A	1.43e-05	17	53	3	IPR016193
Domain	CYT_DCMP_DEAMINASES_1	APOBEC3H APOBEC3G APOBEC3A	1.43e-05	17	53	3	PS00903
Domain	CMP_dCMP_Zn-bd	APOBEC3H APOBEC3G APOBEC3A	1.43e-05	17	53	3	IPR002125
Domain	CYT_DCMP_DEAMINASES_2	APOBEC3H APOBEC3G	8.10e-04	15	53	2	PS51747
Domain	LIM	LDB3 LPXN PXN	9.90e-04	69	53	3	PF00412
Domain	-	LDB3 LPXN PXN	1.03e-03	70	53	3	2.10.110.10
Domain	Znf_LIM	LDB3 LPXN PXN	1.08e-03	71	53	3	IPR001781
Domain	LIM_DOMAIN_1	LDB3 LPXN PXN	1.08e-03	71	53	3	PS00478
Domain	LIM_DOMAIN_2	LDB3 LPXN PXN	1.08e-03	71	53	3	PS50023
Domain	LIM	LDB3 LPXN PXN	1.08e-03	71	53	3	SM00132
Domain	HR1_rho-bd	RTKN2 ATP6V0A4	2.27e-03	25	53	2	IPR011072
Pubmed	Structure-guided analysis of the human APOBEC3-HIV restrictome.	APOBEC3H APOBEC3G APOBEC3A	6.66e-08	6	53	3	24657093
Pubmed	Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.	APOBEC3H APOBEC3G APOBEC3A	1.16e-07	7	53	3	21835787
Pubmed	APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation.	APOBEC3H APOBEC3G APOBEC3A	1.86e-07	8	53	3	24227842
Pubmed	HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.	APOBEC3H APOBEC3G APOBEC3A	5.47e-07	11	53	3	22915799
Pubmed	Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.	APOBEC3H APOBEC3G APOBEC3A	5.47e-07	11	53	3	12683974
Pubmed	Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.	APOBEC3H APOBEC3G APOBEC3A	2.24e-06	17	53	3	24189052
Pubmed	Clinically approved immunomodulators ameliorate behavioral changes in a mouse model of hereditary spastic paraplegia type 11.	RAG1 SPG11	2.28e-06	2	53	2	38435059
Pubmed	Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.	APOBEC3H APOBEC3G	2.28e-06	2	53	2	16571802
Pubmed	Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.	APOBEC3H APOBEC3G	2.28e-06	2	53	2	18827027
Pubmed	APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.	APOBEC3H APOBEC3G	2.28e-06	2	53	2	24361275
Pubmed	The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	22013041
Pubmed	Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	25275135
Pubmed	Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population.	APOBEC3H APOBEC3A	6.83e-06	3	53	2	31322199
Pubmed	Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.	APOBEC3G APOBEC3A	6.83e-06	3	53	2	17727729
Pubmed	HIV-1 Vif adaptation to human APOBEC3H haplotypes.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	24139399
Pubmed	HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	24942576
Pubmed	A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	19939923
Pubmed	APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.	APOBEC3H APOBEC3A	6.83e-06	3	53	2	22457529
Pubmed	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.	APOBEC3H APOBEC3A	6.83e-06	3	53	2	30135250
Pubmed	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.	RAG1 TRPC1	6.83e-06	3	53	2	26674251
Pubmed	Different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	31400856
Pubmed	[Human Papillomavirus Carcinogenesis Mediated by APOBEC Mutagenesis].	APOBEC3G APOBEC3A	6.83e-06	3	53	2	30606934
Pubmed	LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin.	LPXN PXN	6.83e-06	3	53	2	19917054
Pubmed	CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.	PARP1 RNF126	6.83e-06	3	53	2	34388456
Pubmed	A kindlin-3-leupaxin-paxillin signaling pathway regulates podosome stability.	LPXN PXN	6.83e-06	3	53	2	31537712
Pubmed	Regulatory variants of APOBEC3 genes potentially associate with COVID-19 severity in populations with African ancestry.	APOBEC3G APOBEC3A	6.83e-06	3	53	2	38105291
Pubmed	The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness.	APOBEC3G APOBEC3A	6.83e-06	3	53	2	36100631
Pubmed	PARP-1 regulates expression of TGF-β receptors in T cells.	RAG1 PARP1	6.83e-06	3	53	2	23940283
Pubmed	Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	18420796
Pubmed	Evolution of the primate APOBEC3A cytidine deaminase gene and identification of related coding regions.	APOBEC3G APOBEC3A	6.83e-06	3	53	2	22272271
Pubmed	Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.	APOBEC3H APOBEC3G	6.83e-06	3	53	2	34774569
Pubmed	HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.	APOBEC3G APOBEC3A	1.36e-05	4	53	2	21279453
Pubmed	APOBEC3 proteins can copackage and comutate HIV-1 genomes.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	27439715
Pubmed	CEM-T4 cells do not lack an APOBEC3G cofactor.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	19649317
Pubmed	A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	19344514
Pubmed	Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	22203821
Pubmed	Structural features of antiviral DNA cytidine deaminases.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	23787464
Pubmed	Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions.	APOBEC3H APOBEC3A	1.36e-05	4	53	2	18403710
Pubmed	APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.	APOBEC3H APOBEC3G	1.36e-05	4	53	2	23097438
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	DNAJC13 TRIO ZC3H4 CNOT1 AP3D1	1.44e-05	202	53	5	33005030
Pubmed	AID and APOBECs span the gap between innate and adaptive immunity.	APOBEC3H APOBEC3G	2.27e-05	5	53	2	25352838
Pubmed	Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif.	APOBEC3G APOBEC3A	2.27e-05	5	53	2	20012521
Pubmed	A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif.	APOBEC3H APOBEC3G	2.27e-05	5	53	2	25461536
Pubmed	Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.	APOBEC3H APOBEC3G	2.27e-05	5	53	2	25206352
Pubmed	Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.	APOBEC3G APOBEC3A	2.27e-05	5	53	2	24851906
Pubmed	GIT1 utilizes a focal adhesion targeting-homology domain to bind paxillin.	LPXN PXN	2.27e-05	5	53	2	17467235
Pubmed	The von Hippel-Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases.	APOBEC3H APOBEC3G APOBEC3A	3.17e-05	40	53	3	34004371
Pubmed	APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans.	APOBEC3H APOBEC3G	3.40e-05	6	53	2	22720156
Pubmed	Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.	APOBEC3H APOBEC3G	3.40e-05	6	53	2	22205746
Pubmed	Retroelements versus APOBEC3 family members: No great escape from the magnificent seven.	APOBEC3H APOBEC3G	3.40e-05	6	53	2	22912627
Pubmed	Macaques as model hosts for studies of HIV-1 infection.	APOBEC3H APOBEC3G	3.40e-05	6	53	2	23825473
Pubmed	Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses.	LPXN PXN	3.40e-05	6	53	2	10604475
Pubmed	Integral and associated lysosomal membrane proteins.	DNAJC13 ATP6V0A4 SPG11 AP3D1	4.19e-05	126	53	4	17897319
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	SAT1 ZC3H4 PCSK6 ASS1 PEX1 MLLT1 LRRC8B ACY1 PML	4.35e-05	1116	53	9	31753913
Pubmed	Human immunodeficiency virus, restriction factors, and interferon.	APOBEC3H APOBEC3G	4.76e-05	7	53	2	19694548
Pubmed	APOBEC3 proteins mediate the clearance of foreign DNA from human cells.	APOBEC3H APOBEC3A	4.76e-05	7	53	2	20062055
Pubmed	APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.	APOBEC3G APOBEC3A	4.76e-05	7	53	2	16527742
Pubmed	The restriction factors of human immunodeficiency virus.	APOBEC3H APOBEC3G	4.76e-05	7	53	2	23043100
Pubmed	HIV-1 Vif: a guardian of the virus that opens up a new era in the research field of restriction factors.	APOBEC3H APOBEC3G	4.76e-05	7	53	2	23430691
Pubmed	PML-like subnuclear bodies, containing XRCC1, juxtaposed to DNA replication-based single-strand breaks.	PARP1 PML	4.76e-05	7	53	2	30260704
Pubmed	An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.	APOBEC3G APOBEC3A	4.76e-05	7	53	2	11863358
Pubmed	WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis.	RAG1 WAS	4.76e-05	7	53	2	29725003
Pubmed	APOBEC proteins and intrinsic resistance to HIV-1 infection.	APOBEC3G APOBEC3A	6.34e-05	8	53	2	19038776
Pubmed	APOBEC3G: an intracellular centurion.	APOBEC3G APOBEC3A	6.34e-05	8	53	2	19008196
Pubmed	Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.	APOBEC3H APOBEC3G	6.34e-05	8	53	2	23202519
Pubmed	PEX14 is required for microtubule-based peroxisome motility in human cells.	DYNC2H1 PEX1 CNOT1	7.84e-05	54	53	3	21525035
Pubmed	The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation.	APOBEC3H APOBEC3G	8.15e-05	9	53	2	25408426
Pubmed	Neural-specific deletion of the focal adhesion adaptor protein paxillin slows migration speed and delays cortical layer formation.	LPXN PXN	8.15e-05	9	53	2	28935710
Pubmed	Introduction to thematic minireview series: Understanding human immunodeficiency virus-host interactions at the biochemical level.	APOBEC3H APOBEC3G	1.02e-04	10	53	2	23043103
Pubmed	Slit2N/Robo1 inhibit HIV-gp120-induced migration and podosome formation in immature dendritic cells by sequestering LSP1 and WASp.	WAS PXN	1.02e-04	10	53	2	23119100
Pubmed	Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.	APOBEC3H APOBEC3G	1.02e-04	10	53	2	20174454
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	ZC3H4 ASS1 ASCC2 SPG11 CNOT1 AP3D1	1.07e-04	497	53	6	36774506
Pubmed	Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.	PARP1 PML	1.24e-04	11	53	2	23169665
Pubmed	The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.	PARP1 TRIO ZC3H4 CNOT1 ITPRIPL1	1.52e-04	332	53	5	37433992
Pubmed	Customised molecular diagnosis of primary immune deficiency disorders in New Zealand: an efficient strategy for a small developed country.	RAG1 WAS	1.76e-04	13	53	2	19859091
Pubmed	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.	RTKN2 PARP1 DYNC2H1 LPXN WDR81 CNOT1 AP3D1	2.15e-04	807	53	7	30575818
Pubmed	Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry.	TRIO LPXN PXN	2.53e-04	80	53	3	16094384
Pubmed	A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome.	RTKN2 OR2T29 WDR81 OR2T5	2.74e-04	205	53	4	12040188
Pubmed	Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.	APOBEC3H APOBEC3G	3.43e-04	18	53	2	20096141
Pubmed	Defining the membrane proteome of NK cells.	KDM3A PARP1 DNAJC13 LPXN ZDHHC3 CNOT1 AP3D1 ITPRIPL1	3.66e-04	1168	53	8	19946888
Pubmed	Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.	APOBEC3G DCAF11	4.70e-04	21	53	2	22190037
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	PARP1 DNAJC13 TRIO ZC3H4 WDR81 CNOT1 UNC13A	6.20e-04	963	53	7	28671696
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	LDB3 ING1 PCSK6 LPXN PXN ZDHHC3	7.15e-04	709	53	6	22988430
Pubmed	A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.	TRIO ZC3H4 PXN MLLT1 PML	7.57e-04	472	53	5	38943005
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	DNAJC13 ZC3H4 ASCC2 PXN GEN1 CNOT1	7.97e-04	724	53	6	36232890
Pubmed	An Interaction Landscape of Ubiquitin Signaling.	KCTD7 ASCC2 DHX32 RNF126 PML	8.24e-04	481	53	5	28190767
Pubmed	A catalogue of putative HIV-1 protease host cell substrates.	KCTD7 PARP1 WAS	9.10e-04	124	53	3	22944692
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	PEX1 CAMTA2 GEN1 CNOT1 LCMT2 PRDM2 PML	1.24e-03	1084	53	7	11544199
Pubmed	TXLNA enhances TBK1 phosphorylation by suppressing PPM1B recruitment.	PARP1 ASCC2 AKR7A2	1.24e-03	138	53	3	37506885
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	FMNL3 KDM3A ZC3H4 SPG11 CNOT1	1.26e-03	529	53	5	14621295
Pubmed	Characterization of the piRNA complex from rat testes.	KCTD7 KDM3A ZC3H4	1.29e-03	140	53	3	16778019
Pubmed	A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility.	RAG1 PARP1	1.47e-03	37	53	2	19116388
Pubmed	Proximity labeling reveals dynamic changes in the SQSTM1 protein network.	DNAJC13 PXN GEN1 CNOT1	1.48e-03	322	53	4	39098523
Interaction	LRRC31 interactions	PARP1 DNAJC13 TRIO ZC3H4 CNOT1 AP3D1	1.27e-05	205	51	6	int:LRRC31
Cytoband	22q13.1-q13.2	APOBEC3G APOBEC3A	7.83e-06	4	53	2	22q13.1-q13.2
Cytoband	19p13.3	MLLT1 RNF126 AP3D1	2.63e-03	237	53	3	19p13.3
GeneFamily	Apolipoprotein B mRNA editing enzyme catalytic subunits	APOBEC3H APOBEC3G APOBEC3A	2.18e-06	12	40	3	406
GeneFamily	LIM domain containing	LDB3 LPXN PXN	2.99e-04	59	40	3	1218
Coexpression	GSE29615_CTRL_VS_DAY3_LAIV_IFLU_VACCINE_PBMC_DN	RAG1 DNAJC13 LPXN DHX32 SPG11 AP3D1	2.14e-06	195	51	6	M4917
Coexpression	GSE360_CTRL_VS_M_TUBERCULOSIS_DC_UP	PARP1 TRIO LPXN CAMTA2 ACY1 ZDHHC3	2.48e-06	200	51	6	M5154
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	KDM3A RTKN2 APOBEC3G SPG11 CAMTA2	1.75e-06	169	53	5	6614c9851537e4c21b1e45ff0cc3bad07ef9d034
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	KDM3A RTKN2 APOBEC3G SPG11 CAMTA2	1.75e-06	169	53	5	665b958f4a720ca369a8a0abc7fbe8b6e13c8ce5
ToppCell	TCGA-Peripheral_Nervous_System-Primary_Tumor-Paraganglioma-Paraganglioma-3\|TCGA-Peripheral_Nervous_System / Sample_Type by Project: Shred V9	TRIO DYNC2H1 ACY1 LCMT2	2.03e-05	135	53	4	ac20133d4a36f48338b45bffb13e842cb66f83ad
ToppCell	PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-Treg\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	WAS LPXN ASS1 APOBEC3H	4.65e-05	167	53	4	a8fd410967447a95b6c0f6878e6ce614eadb3291
ToppCell	PND03-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B-B_mature\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RAG1 PARP1 WAS APOBEC3H	5.10e-05	171	53	4	656a9f407461dbf5c9c0bd234399e1fef6abce2a
ToppCell	5'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-ILCP\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WAS LPXN ALOXE3 DCAF11	5.71e-05	176	53	4	238244294d08975df6bfa26b2b437db3654408ae
ToppCell	LPS-IL1RA-Lymphocytic_NKT\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	WAS LPXN APOBEC3H APOBEC3G	6.09e-05	179	53	4	5ccf0824611ded5c673d94dff3048aedac12f1a8
ToppCell	droplet-Marrow-BM\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APOBEC3H DCAF11 RNF126 PML	6.36e-05	181	53	4	4169a1527b9c8f5783b8cc44e3a3924f8ed9a5e2
ToppCell	PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PARP1 WAS APOBEC3H PML	6.36e-05	181	53	4	d909821355f4bc9e35387cda6ecf7c56793d9da4
ToppCell	PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PARP1 WAS APOBEC3H PML	6.36e-05	181	53	4	52935c496b45207a173b5ac7812f46210c3f74b0
ToppCell	PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B-B_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PARP1 ASS1 APOBEC3H PML	6.64e-05	183	53	4	956ff95aef9c5521b6a3ba7ac6df0aad242c1c35
ToppCell	Control-Lymphocytic_NKT-iNKT/MAIT\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	WAS LPXN APOBEC3H APOBEC3G	6.64e-05	183	53	4	59e8d07556390828f7557ba3fd2f7d49851498b7
ToppCell	Control-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	WAS LPXN APOBEC3H APOBEC3G	6.64e-05	183	53	4	2c5707ada3442eb7100a2a5f9438d5a2ac53a9e1
ToppCell	facs-Lung-3m-Hematologic-lymphocytic-B_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PARP1 WAS LPXN APOBEC3H	7.22e-05	187	53	4	57f9c9162694c184a8fd6634ee0fad511ca71c9e
ToppCell	facs-Lung-3m-Hematologic-lymphocytic-B_cell-B_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PARP1 WAS LPXN APOBEC3H	7.22e-05	187	53	4	6ce6d3678026101c4397320430433c9f05740883
ToppCell	E18.5-Epithelial\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RTKN2 ATP6V0A4 ASS1 ZDHHC3	7.99e-05	192	53	4	75bc06ce38478f06ba29a2cc3d238aa26e87a951
ToppCell	E18.5-Epithelial-Epithelial_Alveolar\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RTKN2 ATP6V0A4 ASS1 ZDHHC3	8.15e-05	193	53	4	8e750a2b198ad6840a6842a7ddd93623faf7c656
ToppCell	E18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RTKN2 ATP6V0A4 ASS1 ZDHHC3	8.15e-05	193	53	4	6cc09f20dd119236c3c9968f3d16c3eabc0811e2
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|390C / Donor, Lineage, Cell class and subclass (all cells)	KDM3A RTKN2 SPG11 CAMTA2	8.32e-05	194	53	4	88db9f9e80c20ff3474f1f6459dcbdc25aec0b6d
ToppCell	3'-Adult-LargeIntestine-Hematopoietic-T_cells-gdT\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WAS LPXN APOBEC3H APOBEC3G	8.32e-05	194	53	4	eaa5914009556af99eba80e1925db5c95d3a5b5d
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	KDM3A RTKN2 SPG11 CAMTA2	8.32e-05	194	53	4	a71728202493d4858342ea2756ea281cd0d99a3a
ToppCell	Smart-seq2-thymus_(Smart-seq2)-myeloid-myeloid_monocytic\|thymus_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	WAS SAT1 PXN APOBEC3A	8.49e-05	195	53	4	ae98215b7b7f22f1aca690920ce6092dc4a3c7db
ToppCell	Smart-seq2-thymus_(Smart-seq2)-myeloid-myeloid_monocytic-monocyte\|thymus_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	WAS SAT1 PXN APOBEC3A	8.49e-05	195	53	4	6fcab7aa4db958ccad0300adea9aaae52ace5bff
ToppCell	control-Others-Megakaryocytes\|Others / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	WAS SAT1 PXN APOBEC3A	8.65e-05	196	53	4	10d914f1612622f64ac71da04e1995a854a4bec9
ToppCell	droplet-Bladder-nan-24m-Endothelial\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FMNL3 GPR4 LDB3 LCMT2	8.65e-05	196	53	4	9a90dd26e7a43e3fd55e7c5d8354cfa4cdd5a6cc
ToppCell	droplet-Bladder-nan-24m-Endothelial-endothelial_cell\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FMNL3 GPR4 LDB3 LCMT2	8.65e-05	196	53	4	04dfef1bd4ebb0e9469ae80024dc177e469a2560
ToppCell	COVID-19\|World / Condition, Lineage and Cell class	PARP1 APOBEC3H APOBEC3G APOBEC3A	8.83e-05	197	53	4	228f641d79282cc3dc51b95a1f4b0cccfc200735
ToppCell	severe-Myeloid-Neutrophils_2\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	WAS SAT1 APOBEC3A PML	8.83e-05	197	53	4	c8a90d82170cf20e14aebecddcf7cc0ca56cda87
ToppCell	severe-Myeloid-Neutrophils_2\|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	WAS SAT1 APOBEC3A PML	9.00e-05	198	53	4	636878836678a0715550fa09f2e3dac11c4d73fe
ToppCell	BAL-Severe\|BAL / Compartment, Disease Groups and Clusters	PARP1 SAT1 APOBEC3A PML	9.00e-05	198	53	4	f63cfcc57f46094ea0673bbc70ea443ebaca6176
ToppCell	LPS_only-Hematopoietic_Lymphocytic\|LPS_only / Treatment groups by lineage, cell group, cell type	WAS LPXN APOBEC3H APOBEC3G	9.00e-05	198	53	4	e4e362dca57adba90a2be38dce810857baa2f265
ToppCell	Tracheal-10x3prime_v2-Immune_Lymphocytic-T-T_CD4-CD4_TRM/EMRA\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	WAS LPXN APOBEC3H APOBEC3G	9.36e-05	200	53	4	283c55076133de5ce195ccad997ffddc56ed32a2
Drug	Flecainide acetate [54143-56-5]; Down 200; 8.4uM; PC3; HT_HG-U133A	GPR4 TRIO ING1 ALOXE3 LRRC8B TBC1D8B PML	3.72e-07	198	53	7	3761_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	KDM3A GPR4 SAT1 ING1 LPXN DCAF11	4.44e-06	185	53	6	6945_UP
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	KDM3A ING1 TRPC1 LPXN PEX1 PML	4.58e-06	186	53	6	1664_UP
Drug	LY 294002; Up 200; 0.1uM; PC3; HT_HG-U133A	TRPC1 PEX1 PXN ALOXE3 UNC13A PML	6.36e-06	197	53	6	1216_UP
Drug	Deoxycorticosterone [64-85-7]; Down 200; 12.2uM; PC3; HT_HG-U133A	PEX1 PXN DCAF11 TBC1D8B AP3D1 PML	6.36e-06	197	53	6	6758_DN
Drug	benserazide hydrochloride; Up 200; 10uM; SKMEL5; HG-U133A	SAT1 ALOXE3 SPG11 CAMTA2 DCAF11 RNF126	6.55e-06	198	53	6	631_UP
Drug	sulindac sulfone; Up 200; 50uM; MCF7; HG-U133A	TRIO DYNC2H1 PEX1 PXN ZDHHC3 AP3D1	6.74e-06	199	53	6	309_UP
Drug	Parthenolide [20554-84-1]; Up 200; 16.2uM; PC3; HT_HG-U133A	ING1 TRPC1 ALOXE3 TBC1D8B PRDM2	5.11e-05	173	53	5	5105_UP
Drug	AC1L1AS8	RAG1 APOBEC3H CNOT1 LCMT2 AP3D1	5.25e-05	174	53	5	CID000001126
Drug	ICI 182,780; Down 200; 1uM; MCF7; HT_HG-U133A	TRIO PEX1 CAMTA2 DCAF11 RNF126	7.02e-05	185	53	5	6965_DN
Drug	Alsterpaullone; Down 200; 10uM; MCF7; HT_HG-U133A	KDM3A ZC3H4 LRRC8B LCMT2 PRDM2	7.39e-05	187	53	5	7051_DN
Drug	Tracazolate hydrochloride [41094-88-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A	WAS TRPC1 LPXN PXN PML	8.16e-05	191	53	5	7339_UP
Drug	2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A	LPXN RNF126 AP3D1 PRDM2 PML	8.57e-05	193	53	5	1647_UP
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	GPR4 TRIO DCAF11 PRDM2 PML	8.57e-05	193	53	5	5922_UP
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	TRIO ING1 DYNC2H1 ASCC2 RNF126	8.57e-05	193	53	5	1022_DN
Drug	5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA	DYNC2H1 TRPC1 PEX1 PRDM2 PML	8.78e-05	194	53	5	862_UP
Drug	2-Chloropyrazine [14508-49-7]; Down 200; 35uM; MCF7; HT_HG-U133A	ING1 PCSK6 ATP6V0A4 PXN AP3D1	8.78e-05	194	53	5	3570_DN
Drug	Methoxy-6-harmalan [3589-73-9]; Up 200; 18.6uM; MCF7; HT_HG-U133A	LDB3 PCSK6 PXN UNC13A PML	8.78e-05	194	53	5	2893_UP
Drug	Palmatine chloride [3486-67-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A	WAS SAT1 TRIO TRPC1 PCSK6	9.00e-05	195	53	5	4957_DN
Drug	(R)-Propranolol hydrochloride [13071-11-9]; Down 200; 13.6uM; PC3; HT_HG-U133A	WAS ING1 TRPC1 ASCC2 PXN	9.00e-05	195	53	5	5814_DN
Drug	Deoxycorticosterone [64-85-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	ING1 PCSK6 RNF126 CNOT1 PRDM2	9.00e-05	195	53	5	5357_DN
Drug	AG-013608 [351320-38-2]; Down 200; 10uM; PC3; HT_HG-U133A	WAS ING1 TLL2 PXN UNC13A	9.00e-05	195	53	5	6440_DN
Drug	Pempidine tartrate [546-48-5]; Down 200; 13uM; MCF7; HT_HG-U133A	ING1 PCSK6 ATP6V0A4 LPXN PML	9.22e-05	196	53	5	3832_DN
Drug	Methotrexate [59-05-2]; Up 200; 8.8uM; PC3; HT_HG-U133A	WAS TRIO P2RY4 DCAF11 RWDD2A	9.22e-05	196	53	5	6318_UP
Drug	Ethotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A	TRPC1 PCSK6 PEX1 PXN PML	9.22e-05	196	53	5	3892_DN
Drug	Methylatropine nitrate [52-88-0]; Up 200; 11uM; HL60; HT_HG-U133A	RAG1 DYNC2H1 TRPC1 PXN PML	9.22e-05	196	53	5	3116_UP
Drug	Doxorubicin hydrochloride [25316-40-9]; Up 200; 6.8uM; MCF7; HT_HG-U133A	LDB3 SAT1 PCSK6 PXN ALOXE3	9.22e-05	196	53	5	5671_UP
Drug	Nicergoline; Down 200; 8.2uM; PC3; HT_HG-U133A	ING1 PEX1 DCAF11 PRDM2 PML	9.22e-05	196	53	5	2058_DN
Drug	Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A	PCSK6 PXN CAMTA2 DCAF11 PML	9.22e-05	196	53	5	4802_DN
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; PC3; HT_HG-U133A	TRIO TRPC1 PXN DCAF11 TBC1D8B	9.22e-05	196	53	5	6745_DN
Drug	Lorglumide sodium salt [97964-56-2]; Down 200; 8.4uM; MCF7; HT_HG-U133A	WAS TRPC1 PCSK6 RNF126 PML	9.22e-05	196	53	5	5619_DN
Drug	Etomidate [33125-97-2]; Down 200; 16.4uM; HL60; HT_HG-U133A	SAT1 PCSK6 PEX1 TMEM187 PRDM2	9.44e-05	197	53	5	2958_DN
Drug	Nifenazone [2139-47-1]; Up 200; 13uM; PC3; HT_HG-U133A	WAS ING1 RWDD2A PRDM2 PML	9.44e-05	197	53	5	2122_UP
Drug	Trifluoperazine dihydrochloride [440-17-5]; Up 200; 8.4uM; PC3; HT_HG-U133A	LRRC8B DCAF11 TBC1D8B UNC13A PML	9.44e-05	197	53	5	6341_UP
Drug	Dubinidine [22964-77-8]; Up 200; 14.6uM; MCF7; HT_HG-U133A	PCSK6 ALOXE3 AP3D1 UNC13A PML	9.44e-05	197	53	5	6250_UP
Drug	chlorpromazine hydrochloride; Up 200; 1uM; PC3; HT_HG-U133A	TRIO TRPC1 TBC1D8B RNF126 PML	9.44e-05	197	53	5	1217_UP
Drug	Phenethicillin potassium salt [132-93-4]; Down 200; 10uM; MCF7; HT_HG-U133A	ING1 P2RY4 PCSK6 LPXN ALOXE3	9.44e-05	197	53	5	6105_DN
Drug	Chlormezanone [80-77-3]; Down 200; 14.6uM; PC3; HT_HG-U133A	ING1 PEX1 APOBEC3G LRRC8B TBC1D8B	9.67e-05	198	53	5	4636_DN
Drug	Hydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; PC3; HT_HG-U133A	TRIO PCSK6 APOBEC3G PRDM2 PML	9.67e-05	198	53	5	5789_UP
Drug	Budesonide [51333-22-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A	LDB3 TRPC1 PCSK6 LPXN PML	9.67e-05	198	53	5	5431_UP
Drug	Pepstatin A [26305-03-3]; Up 200; 5.8uM; MCF7; HT_HG-U133A	PCSK6 PEX1 ALOXE3 CAMTA2 PML	9.90e-05	199	53	5	3264_UP
Drug	Mebeverine hydrochloride [2753-45-9]; Up 200; 8.6uM; MCF7; HT_HG-U133A	GPR4 ATP6V0A4 PXN PRDM2 PML	9.90e-05	199	53	5	6795_UP
Drug	Homochlorcyclizine dihydrochloride [1982-36-1]; Down 200; 10.4uM; PC3; HT_HG-U133A	GPR4 WAS PXN APOBEC3G PML	9.90e-05	199	53	5	7295_DN
Drug	Calciferol [50-14-6]; Down 200; 10uM; HL60; HT_HG-U133A	DYNC2H1 PCSK6 ALOXE3 RWDD2A PML	9.90e-05	199	53	5	2442_DN
Drug	Butamben [94-25-7]; Down 200; 20.6uM; MCF7; HT_HG-U133A	ING1 PCSK6 PEX1 PXN RNF126	9.90e-05	199	53	5	6093_DN
Drug	Pheniramine maleate [132-20-7]; Down 200; 11.2uM; PC3; HT_HG-U133A	PEX1 PXN DCAF11 RWDD2A TBC1D8B	9.90e-05	199	53	5	4012_DN
Drug	Clomipramine hydrochloride [17321-77-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	WAS TRIO TLL2 PCSK6 PML	1.01e-04	200	53	5	3182_UP
Drug	C0761	APOBEC3G APOBEC3A	1.48e-04	8	53	2	CID006321196
Drug	N-cyclopropylammelide	APOBEC3G APOBEC3A	1.48e-04	8	53	2	CID000592814
Drug	antimony trioxide	PARP1 PML	1.89e-04	9	53	2	ctd:C037554
Drug	quercitrin	KDM3A GPR4 PARP1 WAS SAT1	2.71e-04	247	53	5	ctd:C012526
Drug	orotidine5-phosphate	ASS1 APOBEC3H APOBEC3G	2.87e-04	55	53	3	CID000000968
Drug	orpiment	ASS1 PML	2.89e-04	11	53	2	CID005359595
Drug	ammonium acetate	PARP1 ASS1	4.08e-04	13	53	2	ctd:C018824
Drug	GB-C	LPXN ASS1 PRDM2	4.29e-04	63	53	3	CID004632022
Drug	zenarestat	PEX1 MLLT1 AKR7A2	4.70e-04	65	53	3	CID000005724
Drug	Anisomycin [22862-76-6]; Up 200; 15uM; MCF7; HT_HG-U133A	KDM3A SAT1 TRPC1 LPXN	5.26e-04	160	53	4	5364_UP
Drug	methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate	PARP1 PXN	5.48e-04	15	53	2	ctd:C587228
Drug	Hex-3-enyl acetate	WAS ALOXE3	5.48e-04	15	53	2	CID000015574
Drug	sulforhodamine B	PARP1 SAT1 ING1	6.60e-04	73	53	3	CID000065191
Drug	2'-dC	SAT1 APOBEC3H APOBEC3G APOBEC3A	6.75e-04	171	53	4	CID000000637
Drug	hexonate	ASS1 AKR7A2	7.07e-04	17	53	2	CID000199748
Drug	staurosporine; Up 200; 0.1uM; MCF7; HG-U133A	KDM3A WAS SAT1 RNF126	7.52e-04	176	53	4	423_UP
Drug	3-nonenal	ALOXE3 AKR7A2	7.94e-04	18	53	2	CID005283336
Drug	Thioridazine hydrochloride [130-61-0]; Up 200; 9.8uM; PC3; HT_HG-U133A	LDB3 SAT1 ATP6V0A4 APOBEC3G	8.01e-04	179	53	4	4085_UP
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Up 200; 11.8uM; PC3; HT_HG-U133A	SAT1 TRPC1 ALOXE3 PRDM2	8.18e-04	180	53	4	4652_UP
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	KDM3A ZC3H4 LRRC8B PRDM2	8.52e-04	182	53	4	3887_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	KDM3A LPXN LRRC8B PML	8.52e-04	182	53	4	1661_UP
Drug	Mitoxantrone dihydrochloride [70476-82-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A	ING1 ZC3H4 LCMT2 PRDM2	8.52e-04	182	53	4	5354_DN
Drug	Fendiline hydrochloride [13636-18-5]; Up 200; 11.4uM; MCF7; HT_HG-U133A	GPR4 LDB3 SAT1 ALOXE3	8.70e-04	183	53	4	3190_UP
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	KDM3A PCSK6 LPXN PML	8.70e-04	183	53	4	5599_UP
Drug	Monensin sodium salt [22373-78-0]; Up 200; 5.8uM; PC3; HT_HG-U133A	TRIO ALOXE3 RWDD2A PML	8.70e-04	183	53	4	3704_UP
Drug	L-Aspartic Acid	ASS1 ACY1	8.86e-04	19	53	2	DB00128
Drug	Doxorubicin hydrochloride [25316-40-9]; Down 200; 6.8uM; MCF7; HT_HG-U133A	ING1 ZC3H4 LCMT2 PRDM2	8.87e-04	184	53	4	5671_DN
Drug	Diethylstilbestrol [56-53-1]; Up 200; 15uM; MCF7; HT_HG-U133A	LDB3 P2RY4 ALOXE3 PML	8.87e-04	184	53	4	4369_UP
Drug	Alsterpaullone; Down 200; 10uM; PC3; HT_HG-U133A	KDM3A ZC3H4 LCMT2 PRDM2	8.87e-04	184	53	4	7056_DN
Drug	x tt	PARP1 APOBEC3H APOBEC3G	8.94e-04	81	53	3	CID000005704
Drug	tyrphostin AG-825; Down 200; 25.2uM; MCF7; HT_HG-U133A_EA	ZC3H4 LRRC8B LCMT2 PRDM2	9.06e-04	185	53	4	1114_DN
Drug	Alclometasone dipropionate [667634-13-2]; Up 200; 7.6uM; HL60; HT_HG-U133A	WAS ING1 PCSK6 PXN	9.06e-04	185	53	4	2532_UP
Drug	Dicumarol [66-76-2]; Down 200; 11.8uM; PC3; HT_HG-U133A	TRIO PXN AP3D1 PRDM2	9.42e-04	187	53	4	4323_DN
Drug	GW8510; Down 200; 10uM; MCF7; HT_HG-U133A	ING1 ZC3H4 LCMT2 PRDM2	9.42e-04	187	53	4	7080_DN
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	ING1 P2RY4 LPXN TMEM187	9.61e-04	188	53	4	1667_UP
Drug	Alsterpaullone; Down 200; 10uM; PC3; HT_HG-U133A	KDM3A ZC3H4 LCMT2 PRDM2	9.61e-04	188	53	4	7078_DN
Drug	Helveticoside [630-64-8]; Down 200; 7.4uM; PC3; HT_HG-U133A	PEX1 LRRC8B RWDD2A PML	9.61e-04	188	53	4	3770_DN
Drug	dl-ornithine	SAT1 ASS1 APOBEC3G ACY1	9.61e-04	188	53	4	CID000000389
Drug	Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A	TRIO PXN DCAF11 PRDM2	9.61e-04	188	53	4	4845_DN
Drug	Imipramine hydrochloride [113-52-0]; Up 200; 12.6uM; PC3; HT_HG-U133A	WAS TRIO LRRC8B RWDD2A	9.80e-04	189	53	4	1807_UP
Drug	5-fluoropyrimidine	APOBEC3H APOBEC3G	9.83e-04	20	53	2	CID000069605
Drug	Ciclopirox ethanolamine [41621-49-2]; Down 200; 15uM; HL60; HT_HG-U133A	DYNC2H1 TMEM187 RWDD2A PML	1.00e-03	190	53	4	2456_DN
Drug	Prochlorperazine dimaleate [84-02-6]; Up 200; 6.6uM; HL60; HT_HG-U133A	ING1 DYNC2H1 PCSK6 PEX1	1.00e-03	190	53	4	1286_UP
Drug	Promazine hydrochloride [53-60-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A	TRIO ATP6V0A4 PXN PML	1.00e-03	190	53	4	3833_DN
Drug	CP-319743 [172078-87-4]; Up 200; 10uM; MCF7; HT_HG-U133A	TRIO TRPC1 PCSK6 APOBEC3G	1.02e-03	191	53	4	7486_UP
Drug	0179445-0000 [211246-22-9]; Down 200; 10uM; PC3; HT_HG-U133A	TRPC1 PEX1 RWDD2A PML	1.02e-03	191	53	4	4289_DN
Drug	Disulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A	ING1 PCSK6 ALOXE3 PRDM2	1.02e-03	191	53	4	5729_UP
Drug	Astemizole [68844-77-9]; Down 200; 8.8uM; PC3; HT_HG-U133A	GPR4 WAS LRRC8B PML	1.02e-03	191	53	4	4471_DN
Drug	Prednisolone [50-24-8]; Up 200; 11uM; HL60; HT_HG-U133A	P2RY4 PCSK6 PEX1 LRRC8B	1.02e-03	191	53	4	2393_UP
Drug	Etofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A	SAT1 TRIO PCSK6 PML	1.04e-03	192	53	4	4108_UP
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	SAT1 PCSK6 PXN PML	1.06e-03	193	53	4	7490_UP
Drug	Levodopa [59-92-7]; Down 200; 20.2uM; MCF7; HT_HG-U133A	TRIO ING1 PCSK6 PML	1.06e-03	193	53	4	4394_DN
Drug	LY294002; Up 200; 10uM; MCF7; HG-U133A	GPR4 SAT1 TRIO TBC1D8B	1.06e-03	193	53	4	318_UP
Disease	selenium measurement, response to dietary selenium supplementation	TRIO LRRC8B	4.83e-04	20	48	2	EFO_0006331, EFO_0600021
Disease	Toxic Epidermal Necrolysis	PARP1 PML	1.02e-03	29	48	2	C0014518
Disease	Mycoplasma-Induced Stevens-Johnson Syndrome	PARP1 PML	1.02e-03	29	48	2	C3658301
Disease	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum	PARP1 PML	1.02e-03	29	48	2	C3658302
Disease	Drug-Induced Stevens Johnson Syndrome	PARP1 PML	1.02e-03	29	48	2	C1274933
Disease	Stevens-Johnson Syndrome	PARP1 PML	1.09e-03	30	48	2	C0038325

Protein segments in the cluster

Peptide	Gene	Start	Entry
PVWEENFHFECHNSS	UNC13A	721	Q9UPW8
DAFNQAWHLVAHECP	AKR7A2	341	O43488
DEFKHCWDTFVDHQG	APOBEC3A	156	P31941
SEFKHCWDTFVDHQG	APOBEC3G	341	Q9HC16
ALPHDKFWCQVIFDE	ASCC2	71	Q9H1I8
FADCWENFVDHEKPL	APOBEC3H	141	Q6NTF7
PWTEAAEHYSCVFDH	CAMTA2	556	O94983
LTCWKTFLHPEGDHF	DHX32	531	Q7L7V1
WHSPECEFVRHCIAK	ASS1	326	P00966
AWICGEFSEHLQEPH	AP3D1	486	O14617
DVDSIHPTEFCHNCW	RAG1	166	P15918
CFWKVGHSIRHPDVE	PARP1	56	P09874
LFEHHCEVDVSFGPW	KCTD7	221	Q96MP8
KFIEALGHTWHDTCF	LDB3	681	O75112
TKYVTEHWCEDHFFG	ALOXE3	261	Q9BYJ1
EECIHCAKNFHFHDW	PCSK6	861	P29122
CAKNFHFHDWKCVPA	PCSK6	866	P29122
PFCRSWEIHHFFCEV	OR2T5	171	Q6IEZ7
NHKACVRDVSWHPFE	DCAF11	481	Q8TEB1
WHPEHFVCTHCKEEI	LPXN	171	O60711
WEGCHVDSRVDHLFP	GPR4	6	P46093
HFVAILHKCFDSPWT	LRRC8B	151	Q6P9F7
PFCRSWEIHHFFCEV	OR2T29	171	Q8NH02
ALDRTWHPEHFFCAQ	PXN	431	P49023
AAHNHWPFGTEICKF	P2RY4	96	P51582
SVDWPESFVACEHLF	ITPRIPL1	391	Q6GPH6
EVFHWARESPPDFHK	DYNC2H1	2211	Q8NCM8
AEDFVSPEHVKHCFW	KDM3A	1261	Q9Y4C1
SPEHVKHCFWLTQEF	KDM3A	1266	Q9Y4C1
FWHELHFVEKAAAVS	FMNL3	826	Q8IVF7
VISWNHHEFEVKYEC	DNAJC13	806	O75165
VHCFEIEWEKPEHYA	GEN1	411	Q17RS7
HFVEKVVFWLHDSFP	MLLT1	46	Q03111
FHKHCAIHVFPWDQE	PEX1	306	O43933
HAEEWPFKCEFCVQL	PRDM2	1156	Q13029
HFFDLSQWKHCCEEL	RTKN2	391	Q8IZC4
IEWFHFSCVGLNHKP	ING1	376	Q9UK53
CFEAHQWFLKHEARP	PML	151	P29590
FHDGCIVPWLEQHDS	RNF126	251	Q9BV68
FYHCLVAEVPKEHWT	SAT1	51	P21673
CVEGFKEHCEEFWHT	RWDD2A	196	Q9UIY3
VFKEHWSHDPFEAFK	ACY1	86	Q03154
KNPAFKFWNHEFVHC	CNOT1	2331	A5YKK6
KFWNHEFVHCAPEIE	CNOT1	2336	A5YKK6
ELHEAHPWFEFLVQC	SPG11	1026	Q96JI7
HDFADRKDWDAFHPT	TRPC1	481	P48995
GFHFLHCFEEDWTKC	ZDHHC3	191	Q9NYG2
EVHECFLWVPFSHFN	TBC1D8B	301	Q0IIM8
AEHWTKEHCGAVCFV	WAS	61	P42768
ANFFKEVDECSWPDH	TLL2	571	Q9Y6L7
WGDHCNFSHDIELPK	ZC3H4	406	Q9UPT8
FKWCCFDVHVSQHAP	ATP6V0A4	596	Q9HBG4
HFWSKVCDVLQFHFA	TMEM187	226	Q14656
EPFDEFEEWHLKCAH	LCMT2	291	O60294
HVVSCDGAVHVWDPF	WDR81	1711	Q562E7
PEDVGHCFVTWADKF	TRIO	1366	O75962